

## **Certificate of Analysis for NR-50508**

## Staphylococcus aureus, Strain SR2852

## Catalog No. NR-50508

**Product Description:** *Staphylococcus aureus* (*S. aureus*), strain SR2852 was isolated in 2011 from human blood in California, USA. *S. aureus*, strain SR2852 is a vancomycin-sensitive *S. aureus* (VSSA) strain.

Lot<sup>1</sup>: 70001336 Manufacturing Date: 13JAN2017

| TEST                                       | SPECIFICATIONS                              | RESULTS                                  |
|--|---|--|
| Phenotypic Analysis                        |   |  |
| Cellular morphology                        | Gram-positive cocci                         | Gram-positive cocci                      |
| Colony morphology <sup>2</sup>             | Report results                              | Circular, convex, entire, smooth and     |
| Colony morphology                          | Roport rocuito                              | gray (Figure 1)                          |
| Motility (wet mount)                       | Report results                              | Non-motile                               |
| Hemolysis <sup>2</sup>                     | Report results                              | β-hemolytic                              |
| Biochemical Characterization               | Roport roddio                               | p nomory to                              |
| Catalase                                   | Positive                                    | Positive                                 |
| VITEK® 2 Compact (GP card)                 | ≥ 90% probability of being <i>S. aureus</i> | S. aureus (99% probability) <sup>3</sup> |
| Antibiotic Susceptibility Profile          |   |  |
| VITEK® (AST-GP71 card) <sup>4</sup>        |   |  |
| Beta-lactamase <sup>5</sup>                | Report results                              | Positive                                 |
| Cefoxitin screen                           | Report results                              | Positive                                 |
| Benzylpenicillin                           | Report results                              | Resistant (≥ 0.5 µg/mL)                  |
| Oxacillin                                  | Resistant                                   | Resistant (≥ 4 µg/mL)                    |
| Gentamicin                                 | Report results                              | Resistant (≥ 16 µg/mL)                   |
| Ciprofloxacin                              | Report results                              | Resistant (≥ 8 µg/mL)                    |
| Levofloxacin                               | Resistant                                   | Resistant (≥ 8 µg/mL)                    |
| Moxifloxacin                               | Report results                              | Resistant (≥ 8 µg/mL)                    |
| Clindamycin (inducible resistance)         | Report results                              | Negative                                 |
| Erythromycin                               | Resistant                                   | Resistant (≥ 8 μg/mL)                    |
| Clindamycin                                | Resistant                                   | Resistant (≥ 8 μg/mL)                    |
| Quinupristin/dalfopristin                  | Report results                              | Sensitive (≤ 0.5 μg/mL)                  |
| Linezolid                                  | Sensitive                                   | Sensitive (= 2 µg/mL)                    |
| Daptomycin                                 | Sensitive                                   | Sensitive (= 1 µg/mL)                    |
| Vancomycin                                 | Sensitive                                   | Sensitive (= 1 µg/mL)                    |
| Minocycline                                | Report results                              | Intermediate (= 8 µg/mL)                 |
| Tetracycline                               | Resistant                                   | Resistant (≥ 16 µg/mL)                   |
| Tigecycline                                | Report results                              | Sensitive (≤ 0.25 μg/mL) <sup>6</sup>    |
| Nitrofurantoin                             | Report results                              | Sensitive (≤ 16 μg/mL)                   |
| Rifampicin                                 | Sensitive                                   | Sensitive (≤ 0.5 µg/mL)                  |
| Trimethoprim/sulfamethoxazole              | Resistant                                   | Resistant (≥ 320 µg/mL)                  |
| Etest® antibiotic test strips <sup>7</sup> |   |  |
| Teicoplanin <sup>8</sup>                   | Report results                              | Sensitive (= 1 µg/ml)                    |
| Genotypic Analysis                         |   |  |
| Sequencing of 16S ribosomal RNA gene       | ≥ 99% sequence identity to                  | 100% sequence identity to                |
| (~ 780 base pairs)                         | S. aureus type strain                       | S. aureus type strain                    |
|  | (GenBank: L37597)                           | (GenBank: L37597)                        |
| Purity (post-freeze) <sup>9</sup>          | Consistent with expected colony             | Consistent with expected colony          |
| , ,  | morphology                                  | morphology                               |
| Viability (post-freeze) <sup>2</sup>       | Growth                                      | Growth                                   |

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898



## Certificate of Analysis for NR-50508

<sup>1</sup>NR-50508 was produced by inoculation of the deposited material into Tryptic Soy broth and grown 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar with 5% defibrinated sheep blood kolles which were grown 1 day at 37°C in an aerobic atmosphere to produce this lot.

<sup>2</sup>1 day at 37°C in an aerobic atmosphere on Tryptic Soy agar with 5% defibrinated sheep blood.

<sup>3</sup>Percent probabilities above 90% indicate a close match to the typical biochemical pattern for the given organism, with a percent probability of 99% being a perfect match between the test reaction pattern and the unique biochemical pattern of the given organism or organism group. For additional information, please refer to O'Hara, C. M. and J. M. Miller. "Evaluation of the VITEK 2 ID-GNB Assay for Identification of Members of the Family Enterobacteriaceae and Other Nonenteric Gram-Negative Bacilli and Comparison with the VITEK GNI+ Card." J. Clin. Microbiol. 41 (2003): 2096-2101. PubMed: 12734254.

<sup>4</sup>Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S22 (2012)

<sup>5</sup>The production of beta-lactamase was detected using a Cefinase™ Paper Disc (BBL™ 231650).

<sup>6</sup>MIC Interpretation Guideline: EUCAST Version 4.0 (2014)

<sup>7</sup>1 day at 37°C in an aerobic atmosphere on Mueller Hinton agar

<sup>8</sup>For teicoplanin (bioMérieux Etest<sup>®</sup> 412459), a MIC ≤ 8 μg/mL is sensitive, a MIC = 16 μg/mL is intermediate, and a MIC ≥ 32 μg/mL is resistant.

<sup>9</sup>Purity of this lot was assessed for 8 days at 37°C in an aerobic atmosphere with 5% CO<sub>2</sub> on Tryptic Soy agar with 5% defibrinated sheep blood.



Figure 1: Colony Morphology

**Date:** 06 APR 2017

Signature:

**BEI Resources Authentication** 

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898